Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G1B | P04054 | 1/20 | 0.46 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | SPHK1 | Q9NYA1 | 2/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | GPR84 | Q9NQS5 | 3/20 | 0.39 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Heptane SCHEMBL5761493 | 0.97 | PLA2G1B (0.45) | PLA2G1BPLA2G2ATSHRSPHK1THRB | |
| Hexane SCHEMBL1545339 | 0.97 | PLA2G1B (0.43) | PLA2G1BPLA2G2ATSHRSPHK1THRB | |
| Heptane SCHEMBL5761773 | 0.95 | LMNA (0.43) | PLA2G1BPLA2G2ATSHRSPHK1THRB | |
| Hexane SCHEMBL6143994 | 0.94 | PLA2G1B (0.41) | PLA2G1BPLA2G2ATSHRSPHK1THRB | |
| Hexane SCHEMBL28094651 | 0.92 | SMN1; SMN2 (0.41) | PLA2G1BPLA2G2ATSHRSPHK1THRB | |
| Hexane SCHEMBL9806005 | 0.90 | PLA2G1B (0.39) | PLA2G1BPLA2G2ATSHRSPHK1THRB | |
| Pentane SCHEMBL28094245 | 0.86 | LMNA (0.37) | PLA2G1BPLA2G2ATSHRSPHK1LMNA | |
| Hexane SCHEMBL28464455 | 0.85 | GPR84 (0.43) | TSHRALDH1A1HSD17B10MEN1KMT2A | |
| Heptane SCHEMBL6217 | 0.85 | TSHR (0.61) | TSHRSPHK1THRBLMNAALDH1A1 | |
| Isopropyl Alcohol SCHEMBL3893557 | 0.85 | ALDH1A1 (0.46) | TSHRTHRBLMNAALDH1A1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1370550-B1 | QUINOLYL PROPYL PIPERIDINE DERIVATIVES, THE PREPARATION THEREOF AND COMPOSITIONS CONTAINING SAME | NOVEXEL (FR) | 2007-05-23 | — | — | EP | disclosed |
| EP-1299365-B1 | 2-AMINOTHIAZOLINE DERIVATIVES AND THEIR USE AS NO-SYNTHASE INHIBITORS | AVENTIS PHARMA SA (FR) | 2005-09-28 | — | — | EP | disclosed |
| US-6815547-B2 | ANTIMICROBIAL AGENTS EFFECTIVE AGAINST STAPHYLOCOCCUS, STREPTOCOCCUS, ENTEROCOCCUS | AVENTIS PHARMA S.A. (FR) | 2004-11-09 | — | — | US | disclosed |
| EP-0891362-B1 | PYRROLOPYRROLONE DERIVATIVES AS INHIBITORS OF NEUTROPHIL ELASTASE | GLAXO GROUP LTD (GB) | 2004-03-17 | — | — | EP | disclosed |
| US-20030171369-A1 | Quinolylpropylpiperidine derivatives, their preparation, and compositions containing them | AVENTIS PHARMA S.A. | 2003-09-11 | — | — | US | disclosed |
| US-6602884-B2 | Useful as antibiotics against Staphylococcus, Streptococcus, Enterococcus and Moraxella | AVENTIS PHARMA S.A. (FR) | 2003-08-05 | — | — | US | disclosed |
| EP-1299365-A1 | 2-AMINOTHIAZOLINE DERIVATIVES AND THEIR USE AS NO-SYNTHASE INHIBITORS | Aventis Pharma S.A. (FR) | 2003-04-09 | — | — | EP | disclosed |
| US-20020177606-A1 | Quinolylpropylpiperidine derivatives, their preparation, and compositions containing them | NOVEXEL (FR) | 2002-11-28 | — | — | US | disclosed |
| WO-2001094325-A1 | 2-AMINOTHIAZOLINE DERIVATIVES AND THEIR USE AS NO-SYNTHASE INHIBITORS | AVENTIS PHARMA S.A. (FR) | 2001-12-13 | — | — | WO | disclosed |
| US-6215002-B1 | CYCLIZATION, DEBLOCKING, DEPROTECTION, SULFONATION, CONDENSATION, AMIDATION; ANTIINFLAMMATORY AGENTS; RESPIRATORY SYSTEM DISORDERS | GLAXO WELLCOME INC. | 2001-04-10 | — | — | US | disclosed |
| US-6057457-A | ENZYME INHIBITORS FOR PROTEASE OR ENZYMES OF HYDROLYSIS | GLAXO WELLCOME INC. (US) | 2000-05-02 | — | — | US | disclosed |
| US-5994344-A | BRONCHITIS THERAPY | GLAXO WELLCOME INC. (US) | 1999-11-30 | — | — | US | disclosed |
| EP-0891362-A1 | PYRROLOPYRROLONE DERIVATIVES AS INHIBITORS OF NEUTROPHIL ELASTASE | GLAXO GROUP LIMITED (GB) | 1999-01-20 | — | — | EP | disclosed |
| WO-1997036903-A1 | PYRROLOPYRROLONE DERIVATIVES AS INHIBITORS OF NEUTROPHIL ELASTASE | GLAXO GROUP LIMITED (GB) | 1997-10-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020177606-A1 | Quinolylpropylpiperidine derivatives, their preparation, and compositions containing them | QDPR, MRPL21, RPLP2 | PLA2G1B 3369/4885PLA2G2A 3134/4885TSHR 4643/4885 |
| US-20030171369-A1 | Quinolylpropylpiperidine derivatives, their preparation, and compositions containing them | QDPR, MRPL21, RPLP2 | PLA2G1B 3369/4885PLA2G2A 3134/4885TSHR 4643/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.